CI

At a glance

ClinicalIndex Comparison Record
Phase 3Completed· 150 enrolled
Drug / intervention
Famciclovir +1 moredrug
Likely dose
Famciclovir 125 mgfrom record
Structured eligibility isn't available for this trial yet — see the full criteria in the Eligibility tab below.

Standardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.

Search/NCT01281007
NCT01281007Phase 3Completed
CompareCT.gov

A Prospective, Randomized, Multicenter Study of the Efficacy and Safety of Famciclovir 125 mg Comparing to Aciclovir 200 mg in Patients With Active Recurrent Genital Herpes

EMS·interventional·Posted Jan 21, 2011·Updated Apr 21, 2021

In Brief

A Phase 3 clinical trial evaluating Famciclovir and Aciclovir for GENITAL HERPES. Completed, enrolled 150 participants across 9 sites.

Detailed Summary

Recurrent genital herpes is a commonly occurring sexually transmitted disease caused by herpes simplex virus (HSV). There are effective oral prescription antiviral medicines available to reduce the discomfort of symptoms, such as famciclovir and aciclovir. This is a phase III, multicenter, randomized, parallel-group study to compare the efficacy and safety of treatment with famciclovir (125 mg) versus aciclovir (200 mg) in patients with active recurrent genital herpes.

Study Details

Study Typeinterventional
Allocation--
Masking--
Primary Purpose--
ConditionsGENITAL HERPES
CountriesBrazil
Collaborators--

Timeline

Phase 3CompletedFinished
2011201220132014201520162017201820192020202120222023202420252026
First PostedJan 21, 2011
Enrollment StartJul 1, 2012
Primary CompletionJan 1, 2015
Study CompletionMar 1, 2015
TodayJul 2, 2026
Enrollment to primary: 2.5 yearsPosted 15.4 years ago

Interventions

Famciclovirdrug

Famciclovir 125 mg every 12 hours for 5 days

Aciclovirdrug

Aciclovir 200 mg every 4 hours fo 5 days